Table 2.
Laboratory test results of pulmonary tuberculosis patients notified in Shanghai, China, in the first half of each of 2017 and 2018
| Characteristics | Total n (%) (n = 6047) |
PTB patients of 2017 n (%) (n = 2938) |
PTB patients of 2018 n (%) (n = 3109) |
p-value |
|---|---|---|---|---|
| Sputum smear | < 0.001 | |||
| Negative | 3784 (62.6) | 1812 (61.7) | 1972 (63.4) | |
| Positive | 1802 (29.8) | 850 (28.9) | 952 (30.6) | |
| Not available | 461 (7.6) | 276 (9.4) | 185 (6.0) | |
| Sputum culture | < 0.001 | |||
| Negative | 2123 (35.1) | 1000 (34.0) | 1123 (36.1) | |
| Positive | 2786 (46.1) | 1285 (43.7) | 1501 (48.3) | |
| Not available | 1138 (18.8) | 653 (22.3) | 485 (15.6) | |
| Xpert result for MTB | – | |||
| Negative | 782 (12.9) | – | 782 (25.2) | |
| Positive | 909 (15.0) | – | 909 (29.2) | |
| Not available | 4356 (72.0) | 2938 (100) | 1418 (45.6) | |
| Xpert result for RIF resistancea | – | |||
| Susceptible | 840 (92.4) | – | 840 (92.4) | |
| Resistant | 69 (7.6) | – | 69 (7.6) | |
| Culture-based DST result for RIF resistanceb | 0.784 | |||
| Susceptible | 2188 (78.5) | 1008 (78.4) | 1180 (78.6) | |
| Resistant | 118 (4.2) | 58 (4.5) | 60 (4.0) | |
| Not available | 480 (17.2) | 219 (17.0) | 261 (17.4) |
PTB Pulmonary tuberculosis
Xpert Xpert MTB/RIF
MTB Mycobacteria of tuberculosis
RIF Rifampicin
DST Drug susceptibility test
acalculated among Xpert MTB positive patients
bcalculated among culture positive patients